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Abstract
Background: The simultaneous Occurrence of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia
(AML) has been rarely reported. Most of these cases have been occurring more frequently as a secondary event in
patients receiving chemotherapeutic agents for CLL.
Case presentation: We describe a case of a 77-year-old man who presented with fatigue, pallor and lower limb
pain and weakness. Initial laboratory studies showed Hb 7.7 g/dl, WBC 279.6 × 109/1, PLT 143× 109/1. The peripheral
blood (PB) smear examination showed circulating blast cells (20 %) cells and 50 % lymphocytes, with smudge cells.
A bone marrow examination showed infiltration by two discrete abnormal cell populations, one represents the
leukemic blast cells (60 %) and the other represents small mature lymphocytes (30 %). The immunologic phenotype
of blasts was characterized by the co-expression of CD13, CD33, CD14, CD4, CD15, CD64, HLA-DR, CD11c.
Lymphocytes were characterized by a typical CLL immunophenotype: CD19+, CD5+, CD23+, CD20+ (dim) and
negative for FMC7, CD34, CD10 and TdT. Cytogenetic studies were negative for CLL and AML panels. PCR assays for
AML specific genetic abnormalities were negative. Immunoglobulin gene analysis established the clonal nature of
the B-cell expansion. A final diagnosis of concomitant CLL and AML(FAB: M5) was made.
Conclusion: We have reported a case in which there was simultaneous presentation of AML and CLL. Both forms
of leukemia were well documented by morphology, cytometric analysis and molecular studies. Our findings support
the idea that this rare concurrence of AML and untreated CLL may represent two separate disease processes.
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Background
The association of different malignancies with chronic
lymphocytic leukemia (CLL) such as lung and skin can-
cer has been reported [1–5]. The coexistence of acute
myeloid leukemia (AML) and CLL in the same patient
has been occasionally reported. Most of these cases have
been reported to occur after treatment of CLL with
cytotoxic drugs suggesting that AML may be a second-
ary leukemia [3, 6–8]. Cases in the absence of prior
treatment are exceedingly rare. Only a minority of
reports represent de novo AML following untreated
CLL or concomitant AML and CLL appearing as two
distinct and unrelated malignancies [4, 6, 9–12].
We report a case of concomitant CLL and AML (FAB:
M5) without previous exposure to a cytotoxic agent or
irradiation. Morphologic features, flow cytometric ana-
lysis, molecular and cytogenetic findings of peripheral
blood and Bone marrow samples are discussed.
Case presentation
A 77 year-old man presented with 3 weeks history of
fatigue, pallor and lower limb pain and weakness with
no history of previous exposure to a cytotoxic agent,
irradiation or other medications except for hypertension.
There was no history of fever, night sweats, weight loss,
anorexia, chest pain, headache, blurring of vision or
other relevant symptoms.
Physical examination was significant for enlarged spleen
(3 cm below the costal margin), but no lymphadenopathy,
hepatomegaly, jaundice or gum hypertrophy. Chest X-ray
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was normaland a computerized tomography (CT) scan re-
vealed no lymphoadenopathies.
Initial PB count and smears showed anemia,
thrombocytopenia, and leukocytosis (hemoglobin: 7.7 g/
dl, white blood cells (WBC) 279.6 × 109/1, platelets 45 ×
109/1) with two distinct abnormal populations, the small
cells were corresponding to mature lymphocytes (60 %)
and large cells which corresponded to blast cells (20 %),
and smear cells were also present (Fig. 1).
The immunophenotypic analysis, performed on PB
and bone marrow (BM) aspirate samples confirmed the
morphological findings of the presence of two abnormal
malignant populations. The diagnosis of CLL was con-
firmed by demonstration of expression of mature B-cell
markers (CD19, CD22, CD20 dim), the co-expression of
CD5 and CD23 and the absence of immaturemarkers,
such as CD34, Terminal deoxynucleotidyltransferase
(TdT) and CD10. Similarly, the diagnosis of AML (FAB-
M5) was confirmed by demonstration of expression of
myeloid markers (CD13, CD15, CD33, HLA-DR, MPO)
and monocytic markers (CD4, CD11c, CD14, CD64) and
positive for CD38 and CD56 but negative for CD34 and
CD117 (Fig. 2).
The BM was hypercellular with a diffuse pattern of
infiltration by intermixed lymphocytes and blasts similar
to those observed in the PB (Fig. 3). The lymphocytes
comprised approximately 30 % of the cellularity. Immu-
nohistochemical staining for lymphocytes was positive
for CD5, CD79a (not shown) and CD23 (not shown),
negative for CD3 (Fig. 4). The blasts had monoblastic
features, comprised approximately 60 % of BM cells and
showed positivity byimmunohistochemistry (IHC) for
MPO, CD43 (Fig. 5) and negative for CD3 and CD79a.
The final diagnosis was reported as co-existence of CLL
and AML with monoblastic features (FAB-M5).
On the basis of clinical features and CBC findings, the
patient was started on hydroxyurea 1g three times a day,
Allopurinol and intravenoushydration to prevent tumor
lysis syndrome. His white blood cell count showed
dramatic response within 7 days of treatment within the
normal range (9.1 × 109/L), Hydroxyurea was subse-
quently discontinued.
Later on, the kidney function tests started to deterior-
ate and allopurinol was changed to Rasburicase. He
developed acute on top of chronic kidney disease and he
was started on peritoneal dialysis.
Conventional cytogenetic analysis was performed on
metaphase cells prepared from BM specimen cultured for
24 and 72 h without mitogens, using standard techniques.
The result was reported as a normal karyotype male
[46, XY]. Fluorescence in situ hybridization (FISH)
analysis was performed for common abnormalities
associated with CLL and AML according to the manu-
facturer's instructions. FISH analysis for CLL was
performed using the following probes panel: TP53/CEP17,
D13S319/13q34, IGH/CCND1 (DC,DF), IGH/BCL2
(DC,DF) whereas FISH analysis for AML was performed
using the following probes panel: AML-ETO (DC,DF)/
Fig. 1 PB smear showing circulating blast cells with monocytoid featuresand small mature looking lymphocytes with smudge cell
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Fig. 2 Immunophenotyping on Peripheral Blood sample. Lymphocytes (blue color) were characterized by a typicall CLL immunophenotype: CD19
+, CD5+, CD23+, CD20 + (dim), CD79a + and negative for CD3 whereas the immunologic phenotype of blasts (red color) was characterized by the
co-expression of CD33, CD14, CD15, CD64, HLA-DR, CD11c and MPO
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t(8;21)(q22;q22), PML-RARA (DC,DF)/t(15;17)(q22;q21),
CBFB (DC,BAR)/inv(16)(p13;q22), MLL (DC,BAR)/11q23
and CEP8/D8Z2. FISH results were negative for both CLL
and AML panel- specific abnormalities. RNA isolated
from the BM sample according to the manufacturer's
instructions was subjected to reverse transcriptase-
polymerase chain reaction (RT-PCR) using a nested PCR
reaction, to ascertain the presence or absence of AML
specific abnormalities mentioned before. Similarly, DND
was extracted according to the manufacturer’s instruction
to detect both FLT3 gene mutations (ITD and D835) using
published primers [13, 14] and reported negative for both
AML specific abnormalities and FLT3 gene mutations.
PCR amplifications of genomic DNA established the
clonal nature of the B-cell expansion by the presence of
the IgH gene rearrangement.
Due to old age, comorbid conditions and his perform-
ance status, the patient received palliative therapy with no
curative treatment of his hematological malignancies. The
patient died on the tenth day of hospitalization due to
complications of both metabolic functions and infection.
The association of different malignancies with chronic
lymphocytic leukemia has been reported. The most com-
mon second malignancies are solid tumors, especially lung
and skin cancers [3]. The association of AML and CLL has
been previously described. Most of these cases have been
developed after treatment of CLL with chemotherapeutic
agents suggesting that AML may be a secondary leukemia.
Both disorders have been occasionally diagnosed simultan-
eously in untreated patients, appearing as two distinct and
unrelated malignancies [3, 4].
In the present case study, the PB and BM morphologic
findings are of AML with monoblastic features. FCM
and IHC data are also consistent with AML-M5 but in
addition, flow cytometric studies detect the presence of
a lymphoproliferative process, CLL (CD5+/CD19+). The
association of AML and CLL has been previously
described [4–6]. Cytogenetic and FISH studies per-
formed on interphase cells revealed no cytogenetic
abnormalities such as deletions in chromosomes 6q21,
11q22, 13q14, and 17p13, and trisomy 12(+12) which
are usually detected in 60–80 % of CLL patients [15, 16].
The history of the patient in the present study did not
reveal any exposure to known leukemogenic agents or
chemotherapy for CLL. The diagnoses of both AML and
CLL were simultaneous, although we cannot rule out a
previous asymptomatic indolent course of CLL.
Although the simultaneous occurrence of AML and CLL
is rare, it should not be overlooked as a possible cause of
lymphocytosis in AML patients, as it has been reported
that a reactive polyclonal lymphocytosis may occur in
isolated cases of AML or, more commonly, in myelodys-
plastic syndrome patients [17].
Multiple theories behind the development of simultan-
eous malignancies in patients with CLL have been pro-
posed [11]. The first theory involves immunosuppression
Fig. 3 BM trephine biopsy infiltration by two discrete abnormal cell populations, one represents the leukemic blast cells with monocytoid
features and the other represents small mature lymphocytes
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reported in these patients [18]. Some authors
hypothesize that the simultaneous occurrence of AML
and CLL may be due to a common stem cell defect or
leukemogenic factors or possibly a genetic susceptibility
in some patients [19]. However, concomitant AML and
CLL occurring due to chance cannot be excluded [20].
In treatment-related cases, in addition to decreased
immune competence, the cytotoxicity and DNA damage
induced by chemotherapy are also contributing factors
[1, 5, 21]. However, others have demonstrated that the
phenomenon results from separate karyotype abnormal-
ities in the myeloid and lymphoid lines, triggering two
separate neoplastic events [6, 11, 22–24]. Our findings
support the idea that this rare concurrence of AML and
untreated CLL may represent two separate disease
processes as CLL arises from abnormal population of
CD5+, CD19+ B lymphocytes whereas AML derives
from an abnormal myeloid precursor.
Fig. 4 Immunohistochemical staining forl ymphocytes was positive for CD5 (a) and negative for CD3 (b)
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Conclusions
In summary, we have reported a case in which there was
simultaneous presentation of AML and CLL. Both forms
of leukemia were well documented by morphology,
cytometric analysis and molecular studies. This increases
the number of cases in which concomitant CLL and
AML have been found without previous exposure to a
cytotoxic agent or irradiation. Our findings support the
idea that this rare concurrence of AML and untreated
CLL may represent two separate disease processes.
Abbreviations
AML: Acute myeloid leukemia; BM: Bone marrow; CLL: Chronic lymphocytic
leukemia; CT: Computerized tomography; FAB: French-American-British;
PB: Peripheral blood; PCR: Polymerase chain reaction; TdT: Terminal
deoxynucleotidyltransferase
Acknowledgements
We thank all the Hematology, Histopathology, Cytogenetic and Molecular
Laboratories Staffs for data collection and technical help.
Funding
None.
Availability of data and materials
The data is publicly available or can be requested.
Authors’ contributions
GE carried out the BM, flow cytometry studies and drafted the manuscript. EA,
HO conceived of the study, and participated in its design and coordination and
helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interest
The authors indicated no potential conflicts of interest.
Consent for publication
Written informed consent was obtained for publication.
Ethics approval and consent to participate
This case study was approved by the Departmental Research and ethics
committee of Department of Cental Military laboratory and Blood Bank.
Author details
1Department of Basic Sciences, Hematopathology Division, Princess Nourah
Bint Abdulrahman University, College of Medicine, Riyadh, Saudi Arabia.
2Department of Adult Clinical Hematology and Stem cell Therapy, Prince
Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia. 3Department
of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical
City, PO Box 7897, Riyadh 11159, Kingdom of Saudi Arabia.
Received: 31 December 2015 Accepted: 14 September 2016
References
1. Molica S, Alberti A. Second neoplasms in chronic lymphocytic leukemia:
Analysis of incidence as a function of the length of follow-up.
Haematologica. 1989;74:481–5.
2. Bertoldero G, Scribano G, Podda L, et al. Occurrence of second neoplasm in
chronic lymphocytic leukemia. Experience at Padua hospital between 1979
and 1991. Ann Hematol. 1994;69:195–8.
3. Meloni G, Proia A, Guerrisi V, et al. Acute myeloid leukemia and lung cancer
occurring in a chronic lymphocytic leukemia patient treated with
fludarabine and autologous peripheral blood stem-cell transplantation. Ann
Oncol. 2000;11(11):1493–5.
4. Caballero MD, Gonzalez M, Canizo MC, et al. Concomitant Chronic Lymphocytic
Leukemia (CLL) and Acute Myeloid Leukemia. Complete Remission of CLL
Achieved with High-Dose Cytosine Arabinoside. Leukemia. 1992;6:856–8.
5. Conlan MG, Mosher DF. Concomitant Chronic Lymphocytic Leukemia, Acute
Myeloid Leukemia, and Thrombosis with Protein C Deficiency. Cancer.
1989;63:1398–401.
6. Gottardi M, Valter G, Degan M, et al. Concomitant chronic lymphocytic
leukemia andacute myeloid leukemia: Evidence of simultaneousexpansion
of two independent clones. Leuk Lymphoma. 2006;47(5):885–9.
Fig. 5 Immunohistochemical staining for blast cells was positive for MPO
Al Mussaed et al. BMC Cancer  (2016) 16:739 Page 6 of 7
7. Rund D, Ben-Yehuda D. Therapy-related leukemiaand MDS: evolving
concepts of pathogenesisand treatment. Hematology. 2004;9:179–87.
8. Morrison VA, Rai KR, Peterson BL, et al. Therapy-Related Myeloid Leukemia
Are Observed in Patients withChronic Lymphocytic Leukemia After
Treatmentwith Fludarabine and Chlorambucil: Results of anIntergroup
Study, Cancer and Leukemia Group B9011. Clin Onc. 2002;20(18):3878–84.
9. Stern N, Shemish J, Ramot B. Chronic lymphatic leukemiaterminating in
acute myeloid leukemia: Review of the literature. Cancer. 1981;47:1849–51.
10. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil inindolent chronic
lymphocytic leukemia. N Engl J Med. 1998;338:1506–14.
11. De Filipp Z, Huynh DV, Fazal S, et al. Allogeneic stem cell transplantation
foracute myeloid leukemia with del(7q) following untreated chronic
lymphocytic leukemia. Hematol Oncol Stem Cell Ther. 2012;5(3):165–8.
12. Lai R, Arber DA, Brynes RK, et al. Untreated chronic lymphocytic leukemia
concurrent with or followed by acute myelogenous leukemia or
myelodysplastic syndrome. A report of five cases and review of the
literature. Am J Clin Pathol. 1999;111:373–8.
13. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within
the activation loop of FLT3 in human hematologic malignancies. Blood.
2001;97(8):2434–9.
14. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS
gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–80.
15. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival
in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.
16. Elyamany G, Fadalla K, Elghezal H, et al. Chronic Lymphocytic Leukemia
with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality. Clin Med Insights
Pathol. 2014;7:21–7.
17. Rosenthal NS, Farhi DC. Reactive plasmacytosis and lymphocytosis in acute
myeloid leukemia. Hematol Pathol. 1994;8:43–51.
18. Gómez-Arbonés J, Gallart MA, Mellado A, et al. Concomitant diagnosis of
acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Importance of flow cytometry in the diagnosis of CLL without
lymphocytosis accompanying AML. Eur J Haematol. 1997;59(5):335–7.
19. Lima M, Porto B, Rodrigues M, et al. Cytogenetic Findings in a Patient
Presenting Simultaneously with Chronic Lymphocytic Leukemia and
AcuteMyeloid Leukemia. Cancer Genet Cytogenet. 1996;87:38–40.
20. Goldman JW, Goldman M, Louis J. Statistical approach to chronic
lymphocytic leukemia and acute leukemia. Arch Intern Med. 1978;138:659.
21. Miller MK, Strauchen JA, Nichols KT, Phelps RG. Concurrent chronic
lymphocytic leukemia cutis and acute myelogenous leukemia cutis in a
patient with untreated CLL. Am J Dermatopathol. 2001;23(4):334–40.
22. Ornellas De Souza MH, de Souza FT, Diamond HR, et al. Cytogenetic and
immunophenotypic evidence of independent clonal origins of concomitant
chronic lymphocyticleukaemia and acute myeloid leukaemia. Eur J
Haematol. 2001;66(4):281–3.
23. Katz JB, Curran AL, Zemba-Palko V, Dabrow MB, Denshaw-Burke MT.
Synchronous Diagnosis of Chronic Lymphocytic Leukemia and Acute
Myeloid Leukemia. J Clin Oncol. 2010;28(35):e726–8.
24. Fattizzo B, Radice T, Cattaneo D, Pomati M, Barcellini W, Iurlo A. Three
hematologic malignancies in the same patient: chronic lymphocytic
leukemia, followed bychronic myeloid leukemia and acute myeloid
leukemia. Clin Lab. 2014;60(11):1929–32.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Al Mussaed et al. BMC Cancer  (2016) 16:739 Page 7 of 7
